The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical efficacy of the anti-EBV agent brincidofovir (BCV) in EBV-associated gastric carcinoma (EBVaGC).
 
Tetsu Kamitani
Employment - SymBio Pharmaceuticals
Stock and Other Ownership Interests - Abbvie; Merck
Research Funding - SymBio Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on brincidofovir
 
Masatoshi Hazama
Employment - SymBio Pharmaceuticals
Leadership - SymBio Pharmaceuticals
Stock and Other Ownership Interests - Chugai Pharma; SymBio Pharmaceuticals; Takeda; Takeda (I)
Patents, Royalties, Other Intellectual Property - Patents on brincidofovir
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); SHIONOGI (Inst); Yakult Honsha (Inst)
 
Minori Rosales
Employment - SymBio Pharmaceuticals